Enlivex Therapeutics (XTAE:ENLV) Operating Cash Flow per Share : ₪-2.07 (TTM As of Mar. 2025)

View and export this data going back to 2019. Start your Free Trial

What is Enlivex Therapeutics Operating Cash Flow per Share?

Enlivex Therapeutics's operating cash flow per share for the three months ended in Mar. 2025 was ₪-0.68. Enlivex Therapeutics's operating cash flow per share for the trailing twelve months (TTM) ended in Mar. 2025 was ₪-2.07.

During the past 3 years, the average Operating Cash Flow per Share Growth Rate was 13.60% per year. During the past 5 years, the average Operating Cash Flow per Share Growth Rate was -0.80% per year. During the past 10 years, the average Operating Cash Flow per Share Growth Rate was 32.20% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the OCF Growth Rate using Operating Cash Flow per Share data.

The historical rank and industry rank for Enlivex Therapeutics's Operating Cash Flow per Share or its related term are showing as below:

XTAE:ENLV' s 3-Year OCF Growth Rate Range Over the Past 10 Years
Min: -308 Med: 5.35 Max: 72.4
Current: 13.6

During the past 13 years, Enlivex Therapeutics's highest 3-Year average Operating Cash Flow per Share Growth Rate was 72.40% per year. The lowest was -308.00% per year. And the median was 5.35% per year.

XTAE:ENLV's 3-Year OCF Growth Rate is ranked better than
53.97% of 1221 companies
in the Biotechnology industry
Industry Median: 9.3 vs XTAE:ENLV: 13.60

Enlivex Therapeutics Operating Cash Flow per Share Historical Data

The historical data trend for Enlivex Therapeutics's Operating Cash Flow per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Enlivex Therapeutics Operating Cash Flow per Share Chart

Enlivex Therapeutics Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Operating Cash Flow per Share

Get a 7-Day Free Trial

-2.93

-3.44

-4.56

-4.44

-2.22

Enlivex Therapeutics Quarterly Data
	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25
Operating Cash Flow per Share	Get a 7-Day Free Trial															-0.84	-0.32	-0.43	-0.64	-0.68

Competitive Comparison of Enlivex Therapeutics's Operating Cash Flow per Share

For the Biotechnology subindustry, Enlivex Therapeutics's Price-to-Operating-Cash-Flow, along with its competitors' market caps and Price-to-Operating-Cash-Flow data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Enlivex Therapeutics's Price-to-Operating-Cash-Flow Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Enlivex Therapeutics's Price-to-Operating-Cash-Flow distribution charts can be found below:

* The bar in red indicates where Enlivex Therapeutics's Price-to-Operating-Cash-Flow falls into.

Save Embed

;

Save Embed

;

Enlivex Therapeutics Operating Cash Flow per Share Calculation

Operating Cash Flow per Share is the amount of Cash Flow from Operations per outstanding share of the company's stock.

Enlivex Therapeutics's Operating Cash Flow per Share for the fiscal year that ended in Dec. 2024 is calculated as

Operating Cash Flow per Share (A: Dec. 2024 )	=	Cash Flow from Operations (A: Dec. 2024 )	/	Shares Outstanding (Diluted Average) (A: Dec. 2024 )
	=	-45.559	/	20.514
	=	-2.22

Enlivex Therapeutics's Operating Cash Flow per Share for the quarter that ended in Dec. 2024 is calculated as

Operating Cash Flow per Share (Q: Mar. 2025 )	=	Cash Flow from Operations (Q: Mar. 2025 )	/	Shares Outstanding (Diluted Average) (Q: Mar. 2025 )
	=	-16.195	/	23.759
	=	-0.68

Operating Cash Flow per Share for the trailing twelve months (TTM) ended in Mar. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was ₪-2.07

Enlivex Therapeutics Operating Cash Flow per Share Related Terms

Thank you for viewing the detailed overview of Enlivex Therapeutics's Operating Cash Flow per Share provided by GuruFocus.com. Please click on the following links to see related term pages.

Enlivex Therapeutics Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Enlivex Therapeutics Ltd (XTAE:ENLV) » Definitions » Operating Cash Flow per Share

Comparable Companies

Traded in Other Exchanges

ENLV:USA

Address

14 Einstein Street, Ness Ziona, ISR, 7403618

Website

https://www.enlivex.com

Enlivex Therapeutics Ltd is an Israel-based development-stage biopharmaceutical company. It is focused on developing and commercializing an allogeneic drug pipeline for rebalancing immune hyper-responses. The company's Allocetra is an immunotherapy that is being developed to rebalance a life-threatening unbalanced immune system, using the immune system's own natural regulation mechanisms.